News From SDEE Members

The Aquillius Pitch Competition provides the opportunity for founders to showcase their companies and win FREE incubee membership and lab or office space at Aquillius for 1 year. 1 year Aquillius membership for 1 person 1 year Aquillius lab space (one 6-ft lab bench) or 1 year Aquillius office space...

Hello there! Solo technical founder here. I am a former engineer, former local government sustainability planner piloting a community-scale organics waste management solution. My proof-of-concept facility has been successful so far and we're coming out of the R&D phase to lots of different entities interested in partnering.  I am in...

Sublease is available in Sorrento Mesa at <<market rate: fully furnished ~1100 sqft with executive office, large common office area and large room suitable for experimental work and storage; kitchen access optional. Please send inquiries to Reiko Bachand at [email protected]

Experience levels BS with 2 years experience in pharmaceutical lab - HPLC experience is required BS/MS with 5 to 10 years experience in pharmaceutical lab - HPLC and injectable formulation experience is required Please email [email protected] with your resume

In this post, I share a few thoughts about erythropoietic protoporphyria (EPP), a serious debilitating condition for which there are presently no approved treatments. EPP is a rare inherited disorder of heme biosynthesis characterized by dermal photosensitivity secondary to a partial deficiency of ferrochelatase. In a phenotypically similar X-linked protoporphyria (XLP),...

Neuropore announced advancement of UCB0599 to next phase.  UCB0599 is an orally bioavailable, brain barrier penetrant small molecule that prevents the oligomerization of alpha-synuclein. Alpha-synuclein oligomerization and aggregation is implicated in Parkinson’s disease and other degenerative diseases. By inhibiting misfolding and oligomerization of alpha-synuclein, it is believed that the progression...

Neuropore Therapies announced that it has initiated a Phase 1 clinical trial in healthy volunteers with NPT520-34. This Phase 1 study is designed to evaluate the safety, tolerability and pharmacokinetics of NPT520-34. NPT520-34 is an orally bioavailable, blood-brain barrier penetrating small molecule. Its mode of action is attenuation of neuroinflammation...

Collidion, Inc. and it’s subsidiaries,  Plex Pharmaceuticals & Avenlogics, Inc has an immediate full-time position open for Pharmaceutical & Medical Device Regulatory Affairs Director. Position: Full-time Location: Flexible To apply, visit www.collidion.com/careers   Founded in 2015, Collidion, Inc. is a private healthcare company with two subsidiaries, Avenlogics, Inc. and Plex...

Plex Pharmaceuticals is interested in sub-leasing 1000-1500 Sq. Ft. of laboratory space on a month-to-month or long-term basis. The sub-lessee will have access to common laboratory equipment, chemical fume hood, tissue culture and other general lab instruments. Lab bench with 3-5 knee holes, dedicated office space, wi-fi, shared conference room,...

Presentation by Dr. Tom Insel on July 24th at the Illumina Theater, Alexandria at Torrey Pines. Appetizers and drinks sponsored by Neuropore Therapies. About the event: Dr. Insel will talk about leading edge technologies that may one day be of impact to the care of patients suffering from psychiatric conditions. He will...